- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05873543
Effekten av et smarttelefonassistert hybrid hjerterehabiliteringsprogram hos pasienter med hjertesvikt. (SHCR-HF)
The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:
- Is the novel cardiac rehabilitation model feasible for patients with HF?
- Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Hung-Jui Chuang, MD
- Telefonnummer: 67034 00886-2-23123456
- E-post: rexintwo@gmail.com
Studiesteder
-
-
-
Taipei, Taiwan
- Rekruttering
- Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
-
Ta kontakt med:
- Hung-Jui Chuang, MD
- Telefonnummer: 67034 00886-2-23123456
- E-post: rexintwo@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with heart failure between the ages of 18 and 80 years old.
- NYHA (New York Heart Association) functional classification of 1 to 3.
- Patients must be in a stable condition and under outpatient follow-up.
Exclusion Criteria:
- Patients who have contraindications for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription.
- Patients who are unable to complete cardiopulmonary exercise testing.
- Patients who are unable to follow verbal instructions.
- Patients who are unable to walk independently or pedal a stationary bicycle.
- Patients who are unable to use communication app on a smartphone.
- Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation.
- Patients who do not provide consent to participate in the trial.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: smartphone-assisted hybrid cardiac rehabilitation (SHCR)
Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months. |
The 12-week case manager-led SHCR program includes:
|
|
Ingen inngripen: Usual care
Participants receive usual care including general education and exercise suggestion. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of peak oxygen uptake
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Change of 6 minute walking test
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Adherence to prescribed exercise
Tidsramme: 12 weeks(post-intervention)
|
We will evaluate the percentage of completed prescribed exercises at 12 weeks. |
12 weeks(post-intervention)
|
|
Evaluation of Quality of life
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in 36-Item Short Form Survey(SF-36). |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Depression
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Anxiety
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of physical activity
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of grip strength
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of frailty
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Total cholesterol
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Total cholesterol will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: LDL
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The LDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: HDL
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The HDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Triglyceride
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Triglyceride will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: NT-proBNP
Tidsramme: at baseline, 12 weeks(post-intervention), and 6 months.
|
The NT-proBNP will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Hung-Jui Chuang, MD, Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 202302009RINC
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .